Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Major facilitator superfamily domain-containing protein 2A (MFSD2A) is a sodium-dependent symporter that serves as the primary gateway for essential omega-3 fatty acids, specifically docosahexaenoic acid (DHA) in the form of lysophosphatidylcholine (LPC), into the brain and eyes [1, 3, 8]. Predominantly expressed in the endothelial cells of the blood-brain barrier (BBB), MFSD2A is critical for maintaining the barrier's low permeability by suppressing caveolae-mediated transcytosis through lipid remodeling of the cell membrane [4, 6]. Loss-of-function mutations in the MFSD2A gene lead to severe neurodevelopmental conditions, such as progressive microcephaly and intellectual disability, due to insufficient lipid uptake and subsequent BBB dysfunction [1, 3, 12]. In therapeutic contexts, MFSD2A is a dual-purpose target: its temporary inhibition is being investigated as a molecular switch to open the BBB for enhanced delivery of CNS-targeted drugs, such as nanoparticles or antibodies [4, 5, 10]. Conversely, its upregulation or activation is explored as a neuroprotective strategy to restore barrier integrity in conditions like ischemic stroke, Alzheimer's disease, and traumatic brain injury [5, 10, 13]. Additionally, MFSD2A acts as a tumor suppressor in lung and gastric cancers and is a potential biomarker for monitoring neurodegenerative progression and fetal development [9, 10, 11].
MFSD2A functions as a sodium-dependent symporter that transports lysophosphatidylcholine (LPC) lipids, particularly those containing docosahexaenoic acid (DHA), across the blood-brain barrier (BBB) [1, 3]. This transport process incorporates specific lipids into the endothelial cell membrane, which suppresses caveolae-mediated transcytosis, thereby maintaining the restrictive permeability of the BBB [4, 6].
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Major facilitator superfamily domain-containing protein 2A (MFSD2A) (MFSD2A).